Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death
- 1 November 2006
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 152 (5) , 997-1003
- https://doi.org/10.1016/j.ahj.2006.01.011
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessmentThe American Journal of Cardiology, 2005
- Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-upEuropean Heart Journal, 2004
- Lipoprotein-Associated Phospholipase A 2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General PopulationCirculation, 2004
- Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk ScoresCirculation, 2004
- Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) StudyCirculation, 2004
- Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk ScoreCirculation, 2003
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsNew England Journal of Medicine, 2002
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991
- Myocardial Infarction and Mortality in the Coronary Artery Surgery Study (CASS) Randomized TrialNew England Journal of Medicine, 1984